Patients who are being treated as part of a planned cell therapy at Klinikum Chemnitz gGmbH may have biomaterial (peripheral blood and/or bone marrow) taken up to three times as part of routine clinical checks.
Conditions
Interventions
Group 1: Patients who are being treated as part of a planned cell therapy at Klinikum Chemnitz gGmbH
Sponsors
Klinikum Chemnitz gGmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Signed patient consent - Patients older than 18 years - Patients receiving cellular therapy or cell transplantation as part of routine clinical treatment at Klinikum Chemnitz gGmbH
Exclusion criteria
Exclusion criteria: No specially protected patients are included in the study. (e.g. minors, persons temporarily or permanently incapable of giving consent)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The patient materials will be used to gain new insights, for example into potential biomarkers, therapy effects or risk factors. | — |
Secondary
| Measure | Time frame |
|---|---|
| The material is to be processed in cooperation with the Fraunhofer Institute for Cell and Immunotherapy (FH IZI) and stored in a biobank, making it available for various scientific questions. | — |
Countries
Germany
Contacts
Public ContactMathias Hänel
Klinikum Chemnitz gGmbH
Outcome results
None listed